Criminal Charge Against Outspoken Short Seller Unsettles Wall Street

Some legal experts are questioning whether the government overreached with its claims against Andrew Left.

|

Andrew Left built a reputation on Wall Street as an outspoken investor skilled at making money by uncovering corporate frauds and betting against overvalued stocks. But federal authorities claim that Left sometimes misled his loyal followers about his intentions.

The authorities in Los Angeles filed criminal and civil fraud charges in July against Left, the founder of Citron Research, claiming he generated at least $16 million in illegal trading profits through stock manipulation. Prosecutors and regulators accused Left of using his fame to tell investors to do one thing while he traded the other way, failing to adhere to the price targets he published in reports on stocks.

The charges arose from a yearslong investigation into the activities of several traders known as activist short sellers: investors like Left who publicly publish critical reports on companies and then bet on a decline in those companies’ stock prices. Left was the lone short seller charged with wrongdoing and some legal experts are questioning whether the government overreached with some of its claims against him.

The charges against Left have also unnerved other activist short sellers. Some suggest Left became an easy target given his public profile and because short sellers are sometimes seen as a scourge on Wall Street, where most investors like to see stock prices go up instead of down.

Companies targeted by short sellers often push regulators and lawmakers to go after the investors, who say they feel unfairly maligned. The charges against Left appear to take issue with common practices by activist short sellers. Some have said they are considering revising their disclosures about trading policies.

Short sellers say they help keep markets in check, particularly during times of over-exuberance, when investors may overlook company fundamentals as share prices climb. Activist short sellers often compare themselves to investigative journalists, performing a valuable service by calling out frauds and digging up dirt.

Left, 54, who used to live in Beverly Hills, California, now resides in Boca Raton, Florida. A judge set bail at $5 million, and Left was required to post $1 million in cash or other collateral.

The crux of the criminal and civil charges against Left is that he never intended to trade in a way that was consistent with the recommendations in his reports.

The Securities and Exchange Commission called it a “bait and switch” strategy. “Left bought back stock immediately after telling his readers to sell, and he sold stock immediately after telling his readers to buy,” the agency said.

Federal prosecutors said Left used “exaggerated language” in his commentary and “exploited his ability to move stock prices” with his social media posts.

Legal experts said that authorities seem to be suggesting that when Left put a price target for a company’s stock in his reports — a common practice in stock research across the financial industry — he was bound to adhere to it and trade according to his own advice for a period of time.

“This is a tough case,” said Andrew Calamari, a lawyer with Finn Dixon & Herling and a former director of the New York office of the SEC. “They seem to be saying he made very specific misrepresentations that he was planning to hold a position and he didn’t. People can change their minds.”

James Spertus, a lawyer for Left, said his client, who pleaded not guilty to criminal charges, never deceived investors about his trading intentions.

“There are no lies here,” Spertus said. “Mr. Left is a trader and he is not holding his own investments until the targets are reached. No one expects him to.”

Authorities also contend that Left had financial arrangements with hedge funds, some of which traded around the release of his reports, and that he misled investors by not disclosing those deals. Federal prosecutors said Left lied to an investigator about his dealings with hedge funds.

Authorities have not alleged that Left’s research reports contained false allegations against the companies they covered. Investors and analysts such as Left also have a First Amendment right to recommend to investors to buy or sell a stock.

Gina-Gail S. Fletcher, a professor at Duke University School of Law who specializes in market regulation, said traders are not required to immediately disclose their buy and sell orders. She also said the authorities might have had a hard time building a case against Left if he hadn’t published price targets.

“You are under no obligation to speak, but when you speak you have to be truthful,” she said. Still, there was something “unsatisfying” about the charges as presented, she said.

Representatives for the U.S. Attorney’s Office for the Central District of California and the SEC declined to comment.

Legal experts said the charges against Left seem to overlook the fact that sometimes short sellers must abandon a price target to avoid what’s known as a short squeeze.

Short sellers make money by borrowing shares, selling them and then waiting for the price to fall to buy them back cheaper to return to the lender. In a short squeeze, the price of a stock rises instead of falls, forcing short sellers to buy the shares to limit the loss on their bets.

One of the SEC’s proposed remedies in its civil complaint against Left would forbid him from trading within five days of releasing a report. Some lawyers said that would allow for investors to gang up on Left and generate a short squeeze.

“That five-day period is totally arbitrary,” said Daniel Hawke, a lawyer for the firm Arnold & Porter and a former director of the SEC’s market abuse unit. “Five days in a market that reacts in seconds or minutes to news is onerous and inequitable.”

Edwin Dorsey, who writes The Bear Cave, a newsletter that focuses on corporate fraud and misconduct, said he is surprised that authorities were putting so much emphasis on Left’s price targets.

“Price targets are fluid,” said Dorsey, who said he does not short shares of companies he writes about.

Dorsey said Left is an unusual target for authorities to go after given that he has helped expose fraud at a number of companies, including the pharmaceutical firm Valeant. Left’s firm says on its site that “more than 50 companies” the company has written about have become the subjects of regulatory investigations.

“From my perspective, we are just in an era where there is just so much antipathy to short sellers,” said Carson Block, the founder of Muddy Waters Capital, another well-known activist short selling firm.

Federal authorities served a subpoena and a search warrant on Block and his firm during the investigation that led to charges against Left. The SEC recently notified Block that it did not intend to file charges against him, according to a person briefed on the matter.

“Until we get to a point where a lot of people lose lots of money and see the risks as real,” Block said, “we are going to be decidedly unpopular.”

c.2024 The New York Times Company. This article originally appeared in The New York Times.

Latest News

See all >>

Firms Need to Get Back to the Basics of Organic Growth, Report Urges

Some that use artificial intelligence for prospecting are reporting huge gains in lead generation.

Seniors Outnumber Children in 11 States and Almost Half of Counties

There are still more kids than older adults, but that difference is shrinking as more boomers hit 65.   

BlackRock Aims to Tap Into Texas Reputation

BlackRock launches an ETF to tap into Texas's growing reputation as a magnet for companies, capital and jobs in the United States.

1 in 3 Baby Boomers Vow to Never Sell Their Home

The reluctance of older homeowners to sell makes it more difficult for younger generations to find a home.

That Unexpected Call From Your Doctor’s Office Could Be a ‘Spoofing’ Scam

Scammers can and do fool caller ID systems to trick seniors and steal their personal information.

RIA Firm’s Rethink of Retirement Investing a Finalist for Research Award

Dunham & Associates whitepaper offers a new approach tailored to increasing life expectancies.